The Use of Computer Models in Pharmaceutical Safety Evaluation

被引:11
|
作者
Boyer, Scott [1 ]
机构
[1] AstraZeneca R&D, Global Safety Assessment, Molndal, Sweden
来源
关键词
drug toxicity; in silico; off-target pharmacology; organ toxicity; pharmacophore; QSAR; POTASSIUM CHANNEL; DRUG DEVELOPMENT; BIOLOGICAL-ACTIVITY; CHEMICAL-STRUCTURE; PREDICTION; CARCINOGENICITY; PHARMACOLOGY; TOXICITY; INSIGHTS; PHARMACOPHORE;
D O I
10.1177/026119290903700505
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
With the ever increasing volume of data available to scientists in drug discovery and development, the opportunity to leverage an increasing amount of these data in the assessment of drug safety is clear. The challenge in an environment of increasing data volume is in the structuring and the analysis of these data, such that decisions can be made without excluding information or overstating their meaning. Informatics and modelling play a crucial role in addressing this challenge in two basic ways: a) the data are structured and analysed in a transparent and objective way; and b) new experiments are designed with the model as part of the design process, much like modern experimental physics. Enhancing the use and impact of informatics and modelling on drug discovery is not simply a matter of increasing processor speed and memory capacity. The transformation of raw data to usable, and useful, information is a scientific, technical and, perhaps most importantly, cultural challenge within drug discovery. This review will highlight some of the history, current approaches and promising future directions in this. rapidly expanding a rea.
引用
收藏
页码:467 / 475
页数:9
相关论文
共 50 条
  • [41] SAFETY EVALUATION EXPERIENCE WITH DIGITAL-COMPUTER SOFTWARE
    BELTRACCHI, L
    BULLOCK, JB
    NUCLEAR SAFETY, 1976, 17 (06): : 693 - 700
  • [42] A Safety Evaluation and Countermeasure Analysis on Computer Network Application
    Gu, Qingchuan
    2016 5TH INTERNATIONAL CONFERENCE ON EDUCATION AND EDUCATION MANAGEMENT (EEM 2016), 2016, 92 : 296 - 299
  • [43] Biological pharmaceutical drugs and their analogues: registration, efficacy and safety for the clinical use
    Belousov, Yu. B.
    Zyryanov, S. K.
    Davydovskaya, M. V.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2011, 111 (09) : 19 - 24
  • [44] Towards more realistic safety models through computer simulation
    Crawford, JW
    Gallwey, TJ
    ADVANCES IN OCCUPATIONAL ERGONOMICS AND SAFETY, VOL 2, 1998, 2 : 39 - 42
  • [45] USE OF RISK ASSESSMENT AND SAFETY EVALUATION
    WODICKA, VO
    ACS SYMPOSIUM SERIES, 1984, 239 : 131 - 145
  • [46] A TOXICOLOGY DATABANK BASED ON ANIMAL SAFETY EVALUATION STUDIES OF PHARMACEUTICAL COMPOUNDS
    LUMLEY, CE
    WALKER, SR
    HUMAN TOXICOLOGY, 1985, 4 (04): : 447 - 460
  • [47] Pharmaceutical applications of cyclodextrins .3. Toxicological issues and safety evaluation
    Irie, T
    Uekama, K
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (02) : 147 - 162
  • [48] Pharmaceutical and Safety Profile Evaluation of Novel Selenocompounds with Noteworthy Anticancer Activity
    Marc, Malgorzata Anna
    Dominguez-Alvarez, Enrique
    Latacz, Gniewomir
    Doroz-Plonka, Agata
    Sanmartin, Carmen
    Spengler, Gabriella
    Handzlik, Jadwiga
    PHARMACEUTICS, 2022, 14 (02)
  • [49] Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective
    Ainslie, Garrett R.
    Davis, Myrtle
    Ewart, Lorna
    Lieberman, Linda A.
    Rowlands, David J.
    Thorley, Andrew J.
    Yoder, Gorm
    Ryan, Anne M.
    LAB ON A CHIP, 2019, 19 (19) : 3152 - 3161
  • [50] Safety evaluation using behavioral simulation models
    Ghosh, AK
    Johnson, BW
    Profeta, JA
    ANNUAL RELIABILITY AND MAINTAINABILITY SYMPOSIUM, 1996 PROCEEDINGS, 1996, : 82 - 89